DAbundo L, Bassi C, Callegari E, Moshiri F, Guerriero P, Michilli A
Sci Rep. 2024; 14(1):18551.
PMID: 39122875
PMC: 11315904.
DOI: 10.1038/s41598-024-69548-4.
Yan J, Zhang X, Yu L, Ye M, Chen Y
Onco Targets Ther. 2024; 17:287-295.
PMID: 38586813
PMC: 10999206.
DOI: 10.2147/OTT.S449258.
Chen M, Chen X, Zhang Y, Wang W, Jiang L
J Cancer Res Clin Oncol. 2023; 149(9):6361-6370.
PMID: 36752907
DOI: 10.1007/s00432-023-04621-5.
Li Y, Amaladas N, OMahony M, Manro J, Inigo I, Li Q
PLoS One. 2022; 17(7):e0268244.
PMID: 35849586
PMC: 9292077.
DOI: 10.1371/journal.pone.0268244.
Dianat-Moghadam H, Mahari A, Salahlou R, Khalili M, Azizi M, Sadeghzadeh H
Stem Cell Res Ther. 2022; 13(1):150.
PMID: 35395787
PMC: 8994338.
DOI: 10.1186/s13287-022-02829-9.
Green synthesis and characterization of gold nanoparticles from and their anticancer effects on hepatic carcinoma.
Yang Z, Liu Z, Zhu J, Xu J, Pu Y, Bao Y
Drug Deliv. 2022; 29(1):997-1006.
PMID: 35363110
PMC: 8982465.
DOI: 10.1080/10717544.2022.2056664.
Prostaglandin E2 and Receptors: Insight Into Tumorigenesis, Tumor Progression, and Treatment of Hepatocellular Carcinoma.
Chen C, Guan J, Gu X, Chu Q, Zhu H
Front Cell Dev Biol. 2022; 10:834859.
PMID: 35356289
PMC: 8959932.
DOI: 10.3389/fcell.2022.834859.
Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Unresectable Hepatocellular Carcinoma: Efficacy and Systemic Immune Response.
Yang F, Xu G, Huang J, Yin Y, Xiang W, Zhong B
Front Immunol. 2022; 13:847601.
PMID: 35300339
PMC: 8922415.
DOI: 10.3389/fimmu.2022.847601.
Dicer Enhances Bevacizumab-Related Inhibition of Hepatocellular Carcinoma via Blocking the Vascular Endothelial Growth Factor Pathway.
Wang C, Lv Y, Sha Z, Zhang J, Wu J, Qi Y
J Hepatocell Carcinoma. 2022; 8:1643-1653.
PMID: 35004391
PMC: 8721026.
DOI: 10.2147/JHC.S327258.
VEGFR2 activity on myeloid cells mediates immune suppression in the tumor microenvironment.
Zhang Y, Huang H, Coleman M, Ziemys A, Gopal P, Kazmi S
JCI Insight. 2021; 6(23).
PMID: 34673569
PMC: 8675197.
DOI: 10.1172/jci.insight.150735.
Unexpected Favorable Outcome to PD-1 Antibody Plus Lenvatinib in a Patient With Recurrent Intestinal Follicular Dendritic Cell Sarcoma: A Case Report and Literature Review.
Lei Y, Zhao S, Jiang M
Front Immunol. 2021; 12:653319.
PMID: 34566950
PMC: 8456086.
DOI: 10.3389/fimmu.2021.653319.
Epigenetic Alterations and Mechanisms That Drive Resistance to Targeted Cancer Therapies.
Wajapeyee N, Gupta R
Cancer Res. 2021; 81(22):5589-5595.
PMID: 34531319
PMC: 8595782.
DOI: 10.1158/0008-5472.CAN-21-1606.
Cancer Stem Cells: Emerging Key Players in Immune Evasion of Cancers.
Lei M, Lee T
Front Cell Dev Biol. 2021; 9:692940.
PMID: 34235155
PMC: 8257022.
DOI: 10.3389/fcell.2021.692940.
Green synthesis of gold nanoparticles from and its anticancer effect on liver cancer.
Zhao W, Li J, Zhong C, Zhang X, Bao Y
Drug Deliv. 2021; 28(1):985-994.
PMID: 34042555
PMC: 8171258.
DOI: 10.1080/10717544.2021.1921079.
First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis.
Chiang C, Chan S, Lee S, Choi H
Cancers (Basel). 2021; 13(5).
PMID: 33668100
PMC: 7956424.
DOI: 10.3390/cancers13050931.
Immunotherapy for targeting cancer stem cells in hepatocellular carcinoma.
Dai X, Guo Y, Hu Y, Bao X, Zhu X, Fu Q
Theranostics. 2021; 11(7):3489-3501.
PMID: 33537099
PMC: 7847682.
DOI: 10.7150/thno.54648.
